On January 2, counsel for the Saint Regis Mohawk Tribe filed a motion for discovery and requested an oral hearing concerning which judges will sit on the Patent Trial and Appeal Board (PTAB) panel that oversees its case.
On January 2, counsel for the Saint Regis Mohawk Tribe filed a motion for discovery and requested an oral hearing concerning which judges will sit on the Patent Trial and Appeal Board (PTAB) panel that oversees its case. The move comes after months of controversy over drug maker Allergan’s transfer of its patents for dry-eye drug Restasis to the Tribe in an effort to protect patents from inter partes review (IPR). Under Allergan’s deal, the Tribe invoked sovereign immunity from IPR proceedings in exchange for payment, drawing ire from Congress and industry alike.
Tuesday’s motion suggests that the Tribe may have concerns that backlash against the deal could affect its case; the motion states that the Tribe seeks information on the impartiality of the panel of judges, and on “whether political or third-party pressure has been asserted to reach an outcome inconsistent with the binding Supreme Court and Federal Circuit precedents.”
The Tribe notes that Congress has taken an interest in the proceedings, and implies that political entities could seek to influence the case’s outcome. It also suggests that the impartiality of the panel could be marred by inclusion of judges such as Chief Judge David Ruschke, “a person who has made prior public comments on the issue of sovereign immunity and this case.” (Ruschke previously ruled in an unrelated case that a sovereign entity had waived its right to immunity by having asserted its patents in a federal district court litigation.)
The motion goes on to claim that the United States Patent and Trademark Office has “a direct pecuniary interest in the outcome of this case” because the PTAB collects fees for IPR proceedings.
The motion requests discovery on a number of matters, including the makeup of the merits panel, the dates on which parties were added to the panel, and how the panel’s membership was determined. It also requests disclosure of all ex parte communication that the panel may have had about the case; all communications with Congress, the Executive Branch, or any other parties concerning either the case itself or sovereign immunity in general; information regarding the assignment of judges to other IPR proceedings involving the petitioners; information about the communications of specific judges on the topic of sovereign immunity, and policy determinations covering sovereign immunity.
Finally, the tribe asked for details about the way in which annual bonuses for merits panel members are determined, the annual reviews of all members of the panel, and information on the PTAB’s projections for IPR fees to be collected in 2018 (including the potential for reductions in fees should the Tribe’s sovereign immunity against IPR proceedings be “respected by PTAB”).
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.